What have we learned in dermatology from the biologic therapies?
- 31 March 2006
- journal article
- research article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 54 (3) , S143-S151
- https://doi.org/10.1016/j.jaad.2005.10.059
Abstract
No abstract availableKeywords
This publication has 80 references indexed in Scilit:
- Infliximab in the treatment of moderate to severe atopic dermatitisJournal of the American Academy of Dermatology, 2005
- Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trialJournal of the American Academy of Dermatology, 2004
- Medical treatment of hidradenitis suppurativaExpert Opinion on Pharmacotherapy, 2004
- Combination therapy to treat moderate to severe psoriasisJournal of the American Academy of Dermatology, 2004
- Infliximab for the treatment of hidradenitis suppurativaJournal of the American Academy of Dermatology, 2003
- Cytokine and anticytokine therapy in dermatologyExpert Opinion on Biological Therapy, 2003
- A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasisJournal of the American Academy of Dermatology, 2002
- Treatment of Severe Psoriasis With Anti-CD25 Monoclonal AntibodiesArchives of Dermatology, 2000
- Long-Term Therapy with Recombinant Interferon-Gamma (rIFN-γ) for Atopic DermatitisAnnals of Allergy, Asthma & Immunology, 1998
- Recombinant interferon gamma therapy for atopic dermatitisJournal of the American Academy of Dermatology, 1993